BioAgilytix Remains Committed to Diversity as Global Growth Accelerates

The Latest News from BioAgilytix

July 11, 2018

Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3™-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic

JULY 11, 2018—Richmond, BC, Guilford, CT and Durham, NC—Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its xB3™ proprietary platform technology for the delivery of therapeutics across the blood-brain…

Read More

June 19, 2018

BioAgilytix Partners with Sword Bio to Provide Superior Immunoassays

Innovative Detection Platform Provides BioAgilytix Customers with Important Advancement in Sensitivity and Reliability for their Immunoassays JUNE 19, 2018—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization…

Read More

February 22, 2018

BioAgilytix Europe Successfully Prepared to be a GMP-Compliant Quality Control Testing Laboratory for Product and Batch Release Testing of Biologicals

BioAgilytix’s European Headquarters is Now Equipped to be Selected by Manufacturing and Product License Holders as a GMP Contract Laboratory FEBRUARY 22, 2018—Hamburg, Germany—BioAgilytix, a leading provider of contract bioanalytical…

Read More

January 31, 2018

BioAgilytix Adds Bio-Techne’s Ella™ to Its Portfolio of Industry-Leading Immunoassay Platforms

The Innovative Technology Will Be Used by the Bioanalytical Lab to Support Multiplex Biomarker Analysis JANUARY 31, 2018—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in…

Read More